Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max Kates

Showing results (121-130 of 157) with videos related to

Pageof 16
Sort By:
European Urology|June 28, 2023
Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder CancerMingxiao Feng, Andres Matoso, Gabriel Epstein, et al.
Urologic Oncology|July 20, 2016
Accuracy of urethral frozen section during radical cystectomy for bladder cancerMax Kates, Mark W Ball, Meera R Chappidi, et al.
Oncoimmunology|July 29, 2016
The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladderAlexander S Baras, Charles Drake, Jen-Jane Liu, et al.
Clinical Genitourinary Cancer|December 13, 2021
Safety and Efficacy of Reproductive Organ-Sparing Radical Cystectomy in Women With Variant Histology and Advanced StageSunil H Patel, Shirley Wang, Meredith R Metcalf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2017
Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder CancerMax Kates, Abhijit Date, Takahiro Yoshida, et al.
Annals of Nuclear Medicine|October 26, 2017
Low levels of PSMA expression limit the utility of <sup>18</sup>F-DCFPyL PET/CT for imaging urothelial carcinomaScott P Campbell, Alexander S Baras, Mark W Ball, et al.
European Urology Oncology|August 15, 2019
Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder CancerMax Kates, Thomas R Nirschl, Alex S Baras, et al.
Urologic Oncology|January 13, 2026
Alopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case seriesAnosh Dadabhoy, Chirag Doshi, Mazyar Zahir, et al.
BJU International|April 28, 2026
'BJUI Clinical Dilemma': Recurrent high-grade non-muscle-invasive bladder cancer in 2026Vignesh T Packiam, Peter C Black, James W F Catto, et al.
European Urology Focus|July 8, 2023
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE)Max Kates, Xiangying Chu, Noah Hahn, et al.
Pageof 16

Showing results (121-130 of 157) with videos related to

Sort By:
Pageof 16
European Urology|June 28, 2023
Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder CancerMingxiao Feng, Andres Matoso, Gabriel Epstein, et al.
Urologic Oncology|July 20, 2016
Accuracy of urethral frozen section during radical cystectomy for bladder cancerMax Kates, Mark W Ball, Meera R Chappidi, et al.
Oncoimmunology|July 29, 2016
The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladderAlexander S Baras, Charles Drake, Jen-Jane Liu, et al.
Clinical Genitourinary Cancer|December 13, 2021
Safety and Efficacy of Reproductive Organ-Sparing Radical Cystectomy in Women With Variant Histology and Advanced StageSunil H Patel, Shirley Wang, Meredith R Metcalf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2017
Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder CancerMax Kates, Abhijit Date, Takahiro Yoshida, et al.
Annals of Nuclear Medicine|October 26, 2017
Low levels of PSMA expression limit the utility of <sup>18</sup>F-DCFPyL PET/CT for imaging urothelial carcinomaScott P Campbell, Alexander S Baras, Mark W Ball, et al.
European Urology Oncology|August 15, 2019
Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder CancerMax Kates, Thomas R Nirschl, Alex S Baras, et al.
Urologic Oncology|January 13, 2026
Alopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case seriesAnosh Dadabhoy, Chirag Doshi, Mazyar Zahir, et al.
BJU International|April 28, 2026
'BJUI Clinical Dilemma': Recurrent high-grade non-muscle-invasive bladder cancer in 2026Vignesh T Packiam, Peter C Black, James W F Catto, et al.
European Urology Focus|July 8, 2023
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE)Max Kates, Xiangying Chu, Noah Hahn, et al.
Pageof 16